KIORA PHARMACEUTICALS INC (KPRX) Stock Price, Quote, News and Overview
NASDAQ:KPRX - Nasdaq - US49721T5074 - Common Stock - Currency: USD
KPRX Quote, Performance and Key Statistics
3.47
-0.04 (-1.14%)
The current stock price of KPRX is 3.47 USD. In the past month the price decreased by -8.68%. In the past year, price decreased by -34.61%.
KPRX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.62 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About KPRX
Company Profile
Kiora Pharmaceuticals Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Encinitas, California and currently employs 12 full-time employees. The company went IPO on 2015-02-13. Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The firm is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). KIO-104 is a next generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH), which is being develop for the treatment of Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases, including rheumatoid arthritis, and as such is termed the Ocular Presentation of Rheumatoid Arthritis and Other Autoimmune Diseases (OPRA+).
Company Info
KIORA PHARMACEUTICALS INC
332 Encinitas Boulevard, Suite 102
Encinitas CALIFORNIA US
CEO: Franz Obermayr
Employees: 12
Company Website: https://kiorapharma.com/
Investor Relations: http://ir.kiorapharma.com
Phone: 17817888869
KIORA PHARMACEUTICALS INC / KPRX FAQ
What is the stock price of KIORA PHARMACEUTICALS INC today?
The current stock price of KPRX is 3.47 USD. The price decreased by -1.14% in the last trading session.
What is the ticker symbol for KIORA PHARMACEUTICALS INC stock?
The exchange symbol of KIORA PHARMACEUTICALS INC is KPRX and it is listed on the Nasdaq exchange.
On which exchange is KPRX stock listed?
KPRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KIORA PHARMACEUTICALS INC stock?
8 analysts have analysed KPRX and the average price target is 30.94 USD. This implies a price increase of 791.64% is expected in the next year compared to the current price of 3.47. Check the KIORA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KIORA PHARMACEUTICALS INC worth?
KIORA PHARMACEUTICALS INC (KPRX) has a market capitalization of 10.41M USD. This makes KPRX a Nano Cap stock.
How many employees does KIORA PHARMACEUTICALS INC have?
KIORA PHARMACEUTICALS INC (KPRX) currently has 12 employees.
What are the support and resistance levels for KIORA PHARMACEUTICALS INC (KPRX) stock?
KIORA PHARMACEUTICALS INC (KPRX) has a support level at 3.26 and a resistance level at 3.54. Check the full technical report for a detailed analysis of KPRX support and resistance levels.
Should I buy KIORA PHARMACEUTICALS INC (KPRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KPRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KPRX, evaluating the profitability, health, valuation and growth aspects
- KIORA PHARMACEUTICALS INC (KPRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KIORA PHARMACEUTICALS INC (KPRX) Sales and EPS estimates to see what analysts future expectations are.
- KIORA PHARMACEUTICALS INC (KPRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KIORA PHARMACEUTICALS INC (KPRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- KIORA PHARMACEUTICALS INC (KPRX) Stock Chart to make your own analysis
- KIORA PHARMACEUTICALS INC (KPRX) Latest news and press-releases to stay up to date.
Does KIORA PHARMACEUTICALS INC (KPRX) stock pay dividends?
KPRX does not pay a dividend.
When does KIORA PHARMACEUTICALS INC (KPRX) report earnings?
KIORA PHARMACEUTICALS INC (KPRX) will report earnings on 2025-03-24, after the market close.
What is the Price/Earnings (PE) ratio of KIORA PHARMACEUTICALS INC (KPRX)?
KIORA PHARMACEUTICALS INC (KPRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.15).
What is the Short Interest ratio of KIORA PHARMACEUTICALS INC (KPRX) stock?
The outstanding short interest for KIORA PHARMACEUTICALS INC (KPRX) is 0.68% of its float. Check the ownership tab for more information on the KPRX short interest.
KPRX Technical Analysis
KPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to KPRX. KPRX has an excellent financial health rating, but there are some minor concerns on its profitability.
KPRX Financial Highlights
Over the last trailing twelve months KPRX reported a non-GAAP Earnings per Share(EPS) of -2.15. The EPS increased by 94.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 34.64% | ||
| ROA | 14.41% | ||
| ROE | 18.48% | ||
| Debt/Equity | 0 |
KPRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to KPRX. The Buy consensus is the average rating of analysts ratings from 8 analysts.